Better insight into the molecular and genetic profile of uveal melanoma, such as the interest given in our study to the contribution of STAT family members to the expression of the serotonin receptor HTR2B, will facilitate the identification of new prognostic biomarkers and thus enable us to adapt the existing immunotherapy procedures in order to develop new forms of treatments specifically designed for uveal melanoma patients [57]. This evidence concerns the gene SOAT1 and uveal melanoma.